Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Leyton-Castro NF, Brigido MM, Maranhão AQ. Selection of Antibody Fragments for CAR-T Cell Therapy from Phage Display Libraries. Methods Mol Biol 2020;2086:13-26. [PMID: 31707665 DOI: 10.1007/978-1-0716-0146-4_2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]

For:	Leyton-Castro NF, Brigido MM, Maranhão AQ. Selection of Antibody Fragments for CAR-T Cell Therapy from Phage Display Libraries. Methods Mol Biol 2020;2086:13-26. [PMID: 31707665 DOI: 10.1007/978-1-0716-0146-4_2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]

Number

Cited by Other Article(s)

Martarelli N, Capurro M, Mansour G, Jahromi RV, Stella A, Rossi R, Longetti E, Bigerna B, Gentili M, Rosseto A, Rossi R, Cencini C, Emiliani C, Martino S, Beeg M, Gobbi M, Tiacci E, Falini B, Morena F, Perriello VM. Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors. Int J Mol Sci 2024;25:7231. [PMID: 39000338 PMCID: PMC11242627 DOI: 10.3390/ijms25137231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Revised: 06/25/2024] [Accepted: 06/27/2024] [Indexed: 07/16/2024] Open

Affiliation(s)

Nico Martarelli Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Michela Capurro Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Gizem Mansour Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy; (G.M.); (M.B.); (M.G.)
Ramina Vossoughi Jahromi Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Arianna Stella Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Roberta Rossi Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Emanuele Longetti Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Barbara Bigerna Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Marco Gentili Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Ariele Rosseto Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Riccardo Rossi Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Chiara Cencini Department of Chemistry, Biology, and Biotechnologies, Via del Giochetto, University of Perugia, 06122 Perugia, Italy; (C.C.); (C.E.); (S.M.)
Carla Emiliani Department of Chemistry, Biology, and Biotechnologies, Via del Giochetto, University of Perugia, 06122 Perugia, Italy; (C.C.); (C.E.); (S.M.)
Sabata Martino Department of Chemistry, Biology, and Biotechnologies, Via del Giochetto, University of Perugia, 06122 Perugia, Italy; (C.C.); (C.E.); (S.M.)
Marten Beeg Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy; (G.M.); (M.B.); (M.G.)
Marco Gobbi Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy; (G.M.); (M.B.); (M.G.)
Enrico Tiacci Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Brunangelo Falini Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)
Francesco Morena Department of Chemistry, Biology, and Biotechnologies, Via del Giochetto, University of Perugia, 06122 Perugia, Italy; (C.C.); (C.E.); (S.M.)
Vincenzo Maria Perriello Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, 06132 Perugia, Italy; (N.M.); (M.C.); (R.V.J.); (A.S.); (R.R.); (E.L.); (B.B.); (M.G.); (A.R.); (R.R.); (E.T.); (B.F.)

Collapse

Jahandar-Lashaki S, Farajnia S, Faraji-Barhagh A, Hosseini Z, Bakhtiyari N, Rahbarnia L. Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update. Mol Biotechnol 2024:10.1007/s12033-024-01195-6. [PMID: 38822912 DOI: 10.1007/s12033-024-01195-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Accepted: 05/07/2024] [Indexed: 06/03/2024]

Moazzeni A, Kheirandish M, Khamisipour G, Rahbarizadeh F. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro. Immunobiology 2023;228:152376. [PMID: 37058845 DOI: 10.1016/j.imbio.2023.152376] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2022] [Revised: 02/13/2023] [Accepted: 03/05/2023] [Indexed: 04/16/2023]

Abstract

AIMS

Chimeric Antigen Receptor (CAR) T-cell is a breakthrough in cancer immunotherapy. The primary step of successful CAR T cell therapy is designing a specific single-chain fragment variable (scFv). This study aims to verify the designed anti-BCMA (B cell maturation antigen) CAR using bioinformatic techniques with the following experimental evaluations.

MAIN METHODS

Following the second generation of anti-BCMA CAR designing, the protein structure, function prediction, physicochemical complementarity at the ligand-receptor interface, and biding sites analysis of anti-BCMA CAR construct were confirmed using different modeling and docking server, including Expasy, I-TASSER, HDock, and PyMOL software. To generate CAR T-cells, isolated T cells were transduced. Then, anti-BCMA CAR mRNA and its surface expression were confirmed by real-time -PCR and flow cytometry methods, respectively. To evaluate the surface expression of anti-BCMA CAR, anti-(Fab')2 and anti-CD8 antibodies were employed. Finally, anti-BCMA CAR T cells were co-cultured with BCMA+/- cell lines to assess the expression of CD69 and CD107a as activation and cytotoxicity markers.

KEY FINDINGS

In-silico results approved the suitable protein folding, perfect orientation, and correct locating of functional domains at the receptor-ligand binding site. The in-vitro results confirmed high expression of scFv (89 ± 1.15% (and CD8α (54 ± 2.88%). The expression of CD69 (91.97 ± 1.7%) and CD107a (92.05 ± 1.29%) were significantly increased, indicating appropriate activation and cytotoxicity.

SIGNIFICANCE

In-silico studies before experimental assessments are crucial for state-of-art CAR designing. Highly activation and cytotoxicity of anti-BCMA CAR T-cell revealed that our CAR construct methodology would be applicable to define the road map of CAR T cell therapy.

Collapse

Nanobody-based CAR T cells targeting intracellular tumor antigens. Biomed Pharmacother 2022;156:113919. [DOI: 10.1016/j.biopha.2022.113919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 10/18/2022] [Accepted: 10/24/2022] [Indexed: 11/30/2022] Open

Cienfuegos-Jimenez O, Vazquez-Garza E, Rojas-Martinez A. CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response. Curr Gene Ther 2021;22:303-318. [PMID: 34923939 DOI: 10.2174/1566523222666211217091724] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/14/2021] [Accepted: 10/22/2021] [Indexed: 11/22/2022]